{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:15:58Z","timestamp":1787026558887,"version":"build-2736575974"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors have transformed the landscape of cancer therapy; however, the challenge that most patients do not achieve durable benefits urgently necessitates the development of new strategies that extend beyond mere T-cell activation. mRNA processing\u2014comprising alternative splicing, RNA modifications, and RNA editing\u2014establishes a dynamically regulated connection between the intrinsic characteristics of tumors and anti-tumor immunity. This review systematically summarizes how mechanistic insights into these processes can be translated into concrete approaches that enhance the precision of immunotherapy. We first outline how the widely dysregulated splicing events in tumor cells produce abundant neoantigens at a frequency that significantly exceeds that of gene mutations. A subset of these splice isoforms is shared among patients, offering a unique antigen resource for the development of \u2018off-the-shelf\u2019 mRNA vaccines, thereby circumventing the manufacturing bottleneck associated with personalized vaccines. Concurrently, RNA modifications driven by N6-methyladenosine (m6A) create an immunosuppressive network at the epitranscriptomics level by bidirectionally modulating the stability of immune checkpoint molecules, e.g., Programmed Death-Ligand 1 (PD-L1), and the functional polarization of macrophages and dendritic cells. In parallel, Adenosine Deaminase Acting on RNA 1 (ADAR1)-mediated Adenosine-to-Inosine (A-to-I) editing designates endogenous double-stranded RNA as \u2018self,\u2019 allowing tumors to evade innate immune surveillance and conceal \u2018non-self\u2019 signals. This includes the exploitation of splicing-derived neoantigens for designing personalized or shared mRNA vaccines, the deployment of small-molecule inhibitors targeting FTO, Methyltransferase Like 3 (METTL3), and YTH Domain Family Member 2 (YTHDF2) to alleviate immunosuppression, and the utilization of antisense oligonucleotides to precisely modulate splicing factor activity, thereby reversing T-cell exhaustion. Building on this foundation, the combination of these strategies with immune checkpoint blockade has already demonstrated clear synergistic effects in preclinical models and early-phase trials. Additionally, biomarkers based on splicing signatures and expression levels of modification enzymes show promise for accurately stratifying benefiting populations. Despite challenges such as off-target toxicity, intratumoral heterogeneity, and delivery technologies, cutting-edge tools like single-cell and long-read sequencing are rapidly bridging the translational gap. Strategies targeting mRNA processing are advancing cancer immunotherapy from a model of \u201cbroad-spectrum activation\u201d to a new paradigm of \u201cprecision modulation.\u201d<\/jats:p>","DOI":"10.3389\/fimmu.2026.1844225","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:06:18Z","timestamp":1779689178000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing targeted strategies for cancer immunotherapy by elucidating mRNA processing mechanisms"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiao","family":"Lu","sequence":"first","affiliation":[{"name":"Geriatric Diseases Institute of Chengdu\/Cancer Prevention and Treatment Institute of Chengdu, Department of General Surgery, Chengdu Fifth People\u2019s Hospital(The Second Clinical Medical College, Affiliated Fifth People\u2019s Hospital of Chengdu University of Traditional Chinese Medicine)","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People\u2019s Hospital, University of Electronic Science and Technology of China","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Sichuan Medical Science Academy of University of Electronic Science and Technology of China and Sichuan Provincial People\u2019s Hospital","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688699","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012744","article-title":"m6A-driven transcriptomic rewiring in tumor immune surveillance","volume":"13","author":"Malvi","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1706557","article-title":"Epitranscriptomic control of cancer immunity and therapy resistance","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00877-w","article-title":"Alternative splicing: from tumorigenesis to neoantigen-mediated cancer immunotherapy","volume":"14","author":"Lv","year":"2025","journal-title":"biomark Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105020","article-title":"The evolving role of alternative splicing in cancer stem cell plasticity: From mechanisms to clinical opportunities","volume":"217","author":"Tarmizi","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.03.016","article-title":"Splice it up: atypical transcripts to boost leukemia immunotherapy","volume":"54","author":"Cieri","year":"2021","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-04217-0","article-title":"Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy","author":"Alatawi","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01267-7","article-title":"Nonsense-mediated mRNA decay in human health and diseases: current understanding, regulatory mechanisms and future perspectives","volume":"67","author":"Behera","year":"2025","journal-title":"Mol Biotechnol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2025.06.20.660706","DOI":"10.1101\/2025.06.20.660706","article-title":"SpliceImpactR maps alternative RNA processing events driving protein functional diversity","author":"Wakefield","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-025-01199-0","article-title":"Harnessing alternative splicing for off-the-shelf mRNA neoantigen vaccines in hepatocellular carcinoma","volume":"35","author":"Zhao","year":"2025","journal-title":"Cell Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038670","article-title":"The cancer exome generated by alternative mRNA splicing dilutes predicted HLA class I epitope density","volume":"7","author":"Stranzl","year":"2012","journal-title":"PloS One"},{"key":"B13","unstructured":"Regulations of m6A and other RNA modifications and their roles in cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-021-01447-y","article-title":"METTL3\/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer","volume":"21","author":"Wan","year":"2022","journal-title":"Mol Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1323","article-title":"JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10735-025-10557-6","article-title":"The FTO-YTHDF2 axis drives immune evasion and tumor progression in hepatocellular carcinoma via m6A-dependent FLAD1 regulation","volume":"56","author":"Xu","year":"2025","journal-title":"J Mol Histol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jare.2024.12.026","article-title":"FTO activates PD-L1 promotes immunosuppression in breast cancer via the m6A\/YTHDF3\/PDK1 axis under hypoxic conditions","volume":"76","author":"Wang","year":"2025","journal-title":"J Adv Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.tcb.2024.06.006","article-title":"ADAR1: from basic mechanisms to inhibitors","volume":"35","author":"Rehwinkel","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1621585","article-title":"Deciphering the mechanistic roles of ADARs in cancer pathogenesis, tumor immune evasion, and drug resistance","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116151","article-title":"Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival","volume":"44","author":"\u00c1lvarez-Prado","year":"2025","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41392-026-02574-y","article-title":"Exogenous Epstein\u2013Barr virus nuclear antigen 1 induces ADAR1-driven tumor resistance against immunotherapy","volume":"11","author":"Liu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1702436","article-title":"Roles and mechanisms of NSUN2-mediated RNA m5C modification in cancer progression and immune modulation","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B23","unstructured":"Autoregulated splicing of TRA2\u03b2 programs T cell fate in response to antigen-receptor stimulation | Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03534-z","article-title":"Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion","volume":"72","author":"Wahid","year":"2023","journal-title":"Cancer Immunol Immunother CII"},{"key":"B25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41392-024-02118-2","article-title":"Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells","volume":"10","author":"Zhu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ccell.2021.04.016","article-title":"The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth","volume":"39","author":"Dong","year":"2021","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1186\/s12967-025-07155-1","article-title":"Hypoxia-mediated m6A modulation in hepatocellular carcinoma: a comprehensive review","volume":"23","author":"Jiang","year":"2025","journal-title":"J Transl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10142-025-01743-6","article-title":"Hypoxia-induced m6A modification via YTHDF2 stabilizes PFKL to fuel MDSC glycolysis and hepatocellular carcinoma progression","volume":"25","author":"Guo","year":"2025","journal-title":"Funct Integr Genomics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101909","article-title":"YTHDF2 in inflammation: mechanisms and therapeutic strategies","volume":"13","author":"Liu","year":"2026","journal-title":"Genes Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201701449R","article-title":"ADAR1 attenuates allogeneic graft rejection by suppressing miR-21 biogenesis in macrophages and promoting M2 polarization","volume":"32","author":"Li","year":"2018","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12943-025-02312-y","article-title":"ADAR1-high tumor-associated macrophages induce drug resistance and are therapeutic targets in colorectal cancer","volume":"24","author":"Umeda","year":"2025","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-0916-x","article-title":"Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells","volume":"566","author":"Han","year":"2019","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1038\/s41467-019-09903-6","article-title":"Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900929","article-title":"ADAR1 regulates early T cell development via MDA5-dependent and -independent pathways","volume":"204","author":"Vongpipatana","year":"2020","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02709.x","article-title":"Induction of 150-kDa adenosine deaminase that acts on RNA (ADAR)-1 gene expression in normal T lymphocytes by anti-CD3-epsilon and anti-CD28","volume":"122","author":"Laxminarayana","year":"2007","journal-title":"Immunology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.trecan.2024.10.008","article-title":"Generation of tumor neoantigens by RNA splicing perturbation","volume":"11","author":"Rosenberg-Mogilevsky","year":"2025","journal-title":"Trends Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1437774","article-title":"Neoantigens in cancer immunotherapy: focusing on alternative splicing","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08552-0","article-title":"Tumour-wide RNA splicing aberrations generate actionable public neoantigens","volume":"639","author":"Kwok","year":"2025","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2019-0184","article-title":"Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy","volume":"21","author":"Zhao","year":"2020","journal-title":"Pharmacogenomics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade2886","article-title":"Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0121","article-title":"121 Unlocking the antigenic proteome in clinical cancer tissue to enable personalized cancer immunotherapy","volume":"13","author":"Krizman","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5c14753","article-title":"Reprogramming immunosuppressive niches and the cancer immunity cycle in pancreatic cancer with neoantigen mRNA plus immune adjuvant nanocarrier strategies","volume":"19","author":"Nel","year":"2025","journal-title":"ACS Nano"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102231","article-title":"A comprehensive immune cycle enhancement strategy for alternative splicing-mediated endogenous tumor neoantigens generation and delivery","volume":"34","author":"Wang","year":"2025","journal-title":"Mater Today Bio"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.tig.2020.11.002","article-title":"To NMD or not to NMD: nonsense-mediated mRNA decay in cancer and other genetic diseases","volume":"37","author":"Supek","year":"2021","journal-title":"Trends Genet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.95952","article-title":"Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape","volume":"13","author":"Cook","year":"2025","journal-title":"eLife"},{"key":"B47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12951-025-03872-3","article-title":"Peptide-modified phase-transition nanoparticles co-deliver FTO siRNA and Ce6 for sonodynamic metabolism-immunotherapy of melanoma","volume":"24","author":"Li","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.cmet.2021.04.001","article-title":"Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance","volume":"33","author":"Liu","year":"2021","journal-title":"Cell Metab"},{"key":"B49","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41420-024-01849-z","article-title":"M6A RNA methylation in biliary tract cancer: the function roles and potential therapeutic implications","volume":"10","author":"Bai","year":"2024","journal-title":"Cell Death Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00566","article-title":"Development of orally bioavailable FTO inhibitors with potent antileukemia efficacy","volume":"68","author":"Yang","year":"2025","journal-title":"J Med Chem"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13543776.2024.2447056","article-title":"Patent landscape of small molecule inhibitors of METTL3 (2020-present)","author":"Wu","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-SITC2025.0587","article-title":"587 Phase 1b\/2 dose escalation and expansion study of STC-15, a METTL3 inhibitor, in combination with toripalimab, an anti-PD-1 antibody, in patients with advanced solid tumors","volume":"13","author":"Salkeni","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-024-03402-9","article-title":"METTL14 regulates CD8+T-cell activation and immune responses to anti-PD-1 therapy in lung cancer","volume":"22","author":"Sun","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2025.04.003","article-title":"YTHDF2: a key RNA reader and antitumor target","volume":"46","author":"Xiao","year":"2025","journal-title":"Trends Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adl2171","article-title":"The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion","volume":"9","author":"Xiao","year":"2024","journal-title":"Sci Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02765-6","article-title":"Epitranscriptomic advances in normal and Malignant hematopoiesis","volume":"39","author":"Eleftheriou","year":"2025","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107982","article-title":"CWF19L1 promotes T-cell cytotoxicity through the regulation of alternative splicing","volume":"300","author":"Zhang","year":"2024","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/intimm\/dxae049","article-title":"A splice of life: the discovery, function, and clinical implications of FOXP3 isoforms in autoimmune disease","volume":"37","author":"Weinstein","year":"2024","journal-title":"Int Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adr9933","article-title":"Reprogramming intratumoral Treg cells by morpholino-mediated splicing of FOXP3 for cancer immunotherapy","volume":"10","author":"Li","year":"2025","journal-title":"Sci Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111280","article-title":"An anti-PD-1 antisense oligonucleotide promotes the expression of soluble PD-1 by blocking the interaction between SRSF3 and an exonic splicing enhancer of PD-1 exon 3","volume":"126","author":"Wang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1136\/gutjnl-2024-331903","article-title":"Targeting the oncogenic m6A demethylase FTO suppresses tumourigenesis and potentiates immune response in hepatocellular carcinoma","volume":"74","author":"Chen","year":"2024","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3164\/jcbn.25-180","article-title":"METTL3-mediated m6A modification of CXCR4 drives M2 macrophage polarization and suppresses anti-tumor immunity in esophageal cancer","author":"Sun","year":"2026","journal-title":"J Clin Biochem Nutr"},{"key":"B63","article-title":"Announce 5-year data for intismeran autogene in combination with KEYTRUDA\u00ae (pembrolizumab) demonstrated sustained improvement in the primary endpoint of recurrence-free survival in patients with high-risk stage III\/IV melanoma following complete resection","volume-title":"Merck.com","year":""},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102623","article-title":"Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines","volume":"36","author":"Zhou","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.149038","article-title":"Tumor-retained lipid nanoparticle-microneedle systems for codelivery of SARS-CoV-2 mRNA and indocyanine green for synergistic immuno-photothermal therapy of superficial tumors","volume":"334","author":"Huang","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202401712","article-title":"Cholesterol-derived mannosylated polypeptide-formed lipid nanoparticles for efficient in vivo mRNA delivery","volume":"9","author":"Zeng","year":"2025","journal-title":"Small Methods"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.101893","article-title":"\u03b1-GalCer-LNP ehanced mRNA delivery and activates natural killer T cells for superior tumor immunotherapy","volume":"32","author":"Zhang","year":"2025","journal-title":"Mater Today Bio"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737140.2025.2610271","article-title":"CRISPR-mRNA synergy: toward adaptive cancer immunotherapy","author":"Tanriverdi","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1045130","article-title":"The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer","volume":"10","author":"Luo","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0309","article-title":"SpliceMutr enables pan-cancer analysis of splicing-derived neoantigen burden in tumors","volume":"4","author":"Palmer","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B71","first-page":"2025.08.19.671121","article-title":"Intron retention regulates STAT2 function and predicts immunotherapy response in lung cancer","volume-title":"bioRxiv","author":"Englander","year":"2025"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf1171","article-title":"Single-cell mapping of alternative splicing linked to checkpoint immunotherapy response","volume":"53","author":"Xiong","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biochi.2025.10.015","article-title":"Isoform switching in the CD44\/ESRP1 axis as a driver of EMT and cancer stemness across tumor types","volume":"240","author":"Jankowska","year":"2026","journal-title":"Biochimie"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115985","article-title":"Coordinated expression of retained introns and poison exons in renal cell carcinoma","volume":"44","author":"Mart\u00ednez","year":"2025","journal-title":"Cell Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152368","article-title":"Mechanistic role of FTO in cancer pathogenesis, immune evasion, chemotherapy resistance, and immunotherapy response","volume":"52","author":"Badraldin","year":"2025","journal-title":"Semin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13046-024-03029-4","article-title":"HSPA4 upregulation induces immune evasion via ALKBH5\/CD58 axis in gastric cancer","volume":"43","author":"Suo","year":"2024","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1261\/rna.079953.124","article-title":"Multifaceted roles of RNA editing enzyme ADAR1 in innate immunity","volume":"30","author":"Jarmoskaite","year":"2024","journal-title":"RNA"},{"key":"B78","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1038\/s41467-025-62309-5","article-title":"Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1\/2-mutant cancers","volume":"16","author":"Chabanon","year":"2025","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"9486","DOI":"10.1038\/s41598-025-93695-x","article-title":"Comprehensive systems biology analysis reveals splicing factor contributions to cutaneous melanoma progression","volume":"15","author":"Zhu","year":"2025","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415839","article-title":"The nuclear GYF protein CD2BP2\/U5-52K is required for T cell homeostasis","volume":"15","author":"Bertazzon","year":"2024","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.08.002","article-title":"ADAR1 prevents liver injury from inflammation and suppresses interferon production in hepatocytes","volume":"185","author":"Wang","year":"2015","journal-title":"Am J Pathol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03083-y","article-title":"Bioinformatic analysis of single-cell RNA sequencing dataset dissects cellular heterogeneity of triple-negative breast cancer in transcriptional profile, splicing event and crosstalk network","volume":"25","author":"Qiu","year":"2023","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"B83","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s42003-024-06460-7","article-title":"Frequency-dependent selection of neoantigens fosters tumor immune escape and predicts immunotherapy response","volume":"7","author":"Chen","year":"2024","journal-title":"Commun Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-022-01304-5","article-title":"Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application","volume":"15","author":"Zhang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s11033-025-11421-2","article-title":"Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects","volume":"53","author":"Prabhu","year":"2026","journal-title":"Mol Biol Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12929-024-01082-x","article-title":"Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens","volume":"31","author":"Chi","year":"2024","journal-title":"J BioMed Sci"},{"key":"B87","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43856-025-01235-5","article-title":"Nanopore based RNA methylation profiling of a circulating lung cancer biomarker","volume":"5","author":"Sanchez-Delgado","year":"2025","journal-title":"Commun Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"6654","DOI":"10.1038\/s41467-025-60902-2","article-title":"Single cell and spatial alternative splicing analysis with Nanopore long read sequencing","volume":"16","author":"Fu","year":"2025","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:06:20Z","timestamp":1779689180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1844225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":88,"alternative-id":["10.3389\/fimmu.2026.1844225"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1844225","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1844225"}}